CME: Oncology On-Que: Expert Answers to Common Questions for Optimizing Platinum-Refractory NSCLC Treatment

Be part of the knowledge.

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Oncology On-Que: Expert Answers to Common Questions for Optimizing Platinum-Refractory NSCLC Treatment

Oncology On-Que: Expert Answers to Common Questions for Optimizing Platinum-Refractory NSCLC Treatment
Dr. Bauml reviews questions about molecular testing, biomarkers in immunotherapy, and treatment of rapidly progressing disease.

Available credits: 0.50

Time to complete: 30 minutes


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Despite the importance of genomic profiling and the advent of targeted therapies, chemotherapeutic strategies remain a cornerstone treatment for patients with advanced non–small cell lung cancer (NSCLC). This includes those patients without actionable mutations in the treatment-naive setting as well as patients with NSCLC that progresses on first-line platinum therapy, and NSCLC with genetic alterations that develops resistance to targeted therapies.

    AXIS routinely collects and analyzes data gathered from participants in our live grand rounds programs. These questions provide incredible insight regarding the persistent challenges that clinicians face when trying to optimize treatment planning to verify where clinical practice gaps exist. This activity will provide expert answers to questions asked during a recent grand rounds series on NSCLC.  

  • Faculty

    Joshua Bauml, MD
    Assistant Professor of Medicine
    Perelman School of Medicine at University of Pennsylvania
    Philadelphia, PA

  • Learning Objectives

    At the conclusion of this activity, participants should be better able to:

    • Use biomarker testing and patient characteristics to identify which patients have an actionable mutation target versus those that do not to guide treatment selection for NSCLC
    • Analyze treatment options for patients with advanced NSCLC that does not have an actionable mutation target and has progressed on or after prior platinum-based therapy, and select appropriate treatment for these patients
    • Assess emerging combination approaches in clinical trials for the treatment of NSCLC that has progressed on or after platinum-based therapy
  • Target Audience

    This activity is intended for medical oncologists, thoracic oncologists, pulmonologists, pathologists, oncology nurses, and other healthcare professionals.

  • Disclosure of Conflicts of Interest

    AXIS Medical Education requires instructors, planners, managers, and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by AXIS for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

    AXIS will identify, review, and resolve all conflicts of interest that faculty, authors, activity directors, planners, managers, peer reviewers, or relevant staff disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. Disclosure information for speakers, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.

    The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

    Name of Faculty or Presenter

    Reported Financial Relationship

    Joshua Bauml, MD


    Joshua Bauml, MD, reported a financial interest/relationship or affiliation in the form of Advisory board/consulting, Boehringer Ingelheim; Guardant Health, Inc; Bristol-Myers Squibb Co; AstraZeneca Pharmaceuticals LP; Celgene Corp; Merck & Co, Inc; Genentech, Inc; Contracted research, Merck & Co, Inc; Bayer HeatlhCare, Inc; Novartis Pharmaceuticals Corp; Incyte Corp

    The planners and managers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

    The following AXIS planners and managers, Linda Gracie-King, MS; Jocelyn Timko, BS; Stephanie Sutphin, PharmD; and Marilyn Haas, PhD, RN, CNS, ANP-BC hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest of any amount during the past 12 months.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Credit Designation for Physicians

    AXIS Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™.

    Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Credit Designation for Nursing

    AXIS Medical Education designates this continuing nursing education activity for 0.5 contact hours.

    Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

    AXIS Contact Information

    For information about the certification of this activity, please contact AXIS at

  • Provided by

  • Commercial Support

    This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding visit

  • Disclosure of Unlabeled Use

    This educational activity may contain discussion of agents that are not approved for use by the FDA and/or investigational (“off-label”) uses of agents that are approved by the FDA. The planners of this activity do not recommend the use of any agent outside of its labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each agent for information on its approved indications, contraindications, warnings, and other, related information.

  • Disclaimer

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

  • Method of Participation and Request for Credit

    To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately.

    There is no fee for this educational activity.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

Facebook Comments

You must be in to display playlists.

Get a Dose of ReachMD in Your Inbox
and Practice Smarter Medicine

Stay current with the best in medical education.